What is the efficacy of bortezomib in the treatment of refractory multiple myeloma (MM)?

Updated: Mar 06, 2020
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Bortezomib has a well-established role as salvage therapy, based on a phase III randomized trial showing a response rate of 38% versus 18% in patients receiving dexamethasone only. [53] Median progression-free survival was 6.22 months in the bortezomib arm versus 3.49 months in the dexamethasone-only group.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!